Zenner Patrick J - Jan 2, 2025 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Role
Director
Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Patrick Zenner
Stock symbol
RNAC
Transactions as of
Jan 2, 2025
Transactions value $
$0
Form type
4
Date filed
1/6/2025, 04:20 PM
Previous filing
Jan 4, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAC Common Stock Award $0 +2.6K +33.44% $0.00 10.4K Jan 2, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNAC Stock Option (Right to Buy) Award $0 +7.8K $0.00 7.8K Jan 2, 2025 Common Stock 7.8K $16.93 Direct
holding RNAC Stock Option (Right to Buy) 7.6K Jan 2, 2025 Common Stock 7.6K $19.66 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026.
F2 On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F3 This award vests in 36 equal monthly installments following the date of grant, so that it shall be fully vested on January 2, 2027.